Fig. 6: Genomic alterations and chemotherapy sensitivity associated with the prognostic risk model in NSCLC. | npj Precision Oncology

Fig. 6: Genomic alterations and chemotherapy sensitivity associated with the prognostic risk model in NSCLC.

From: G0S2: a potential target for NSCLC identified through prognostic models from multi-Omic analysis of regulatory T cell metabolic genes

Fig. 6

Single nucleotide variations (SNVs) were compared between high- and low-risk NSCLC patients, with higher mutation frequencies observed in genes such as KRAS, RP1L1 and ASTN1 in the high-risk group (A). Copy number variation (CNV) analysis revealed more extensive amplifications in the high-risk group, especially at chromosomes 3q, 7p and 11q (B, C). Spearman correlation analysis showed that the IC50 values of BMS_536924, TANK_1366, linsitinib, JNJ38877605, refametini, and PARP_9495 were negatively correlated with risk scores (D), while the IC50 values of GSK690693, PHA_665752, CD532, amuvatinib, venetoclax and Ara-G were positively correlated (E).

Back to article page